regardless of positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from PBMs. The organizations are typically creating barriers to reimbursement, such as steep expense criteria and approval